Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study

OBJECTIVESCYP3A4 is involved in the oxidative metabolism of many drugs and xenobiotics including the HMG-CoA reductase inhibitor simvastatin. The objective of this study was to investigate whether a new CYP3A4 functional single nucleotide polymorphism (SNP) in intron 6 (CYP3A4*22) modifies the effec...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacogenetics and genomics 2011-12, Vol.21 (12), p.861-866
Hauptverfasser:	Elens, Laure, Becker, Matthijs L, Haufroid, Vincent, Hofman, Albert, Visser, Loes E, Uitterlinden, André G, Stricker, Bruno Ch, van Schaik, Ron H.N
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Alleles Biological and medical sciences Cholesterol - genetics Cholesterol - metabolism Cohort Studies Cytochrome P-450 CYP3A - genetics Disorders of blood lipids. Hyperlipoproteinemia Female General pharmacology Genotype Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Introns Male Medical sciences Metabolic diseases Middle Aged Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions Pharmacology. Drug treatments Polymorphism, Single Nucleotide Simvastatin - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!